Xyphos Biosciences Inc.
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as AvidBiotics Corp. (to 2018)
1
Ending by 2030
Dec 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Non-natural MIC proteins (US 9,079,969) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Non-Natural NKG2D Receptors That Do Not Directly Signal the Cells to Which They Are Attached (US 11,957,714) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,079,969 | Non-natural MIC proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,658,765 | Non-natural MIC proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,796,420 | Non-natural MIC proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 10,259,858 | Insertable Variable Fragments of Antibodies and Modified ALPHA1-ALPHA2 Domains of NKG2D Ligands, and Non-Natural NKG2D Ligands That Bind Non-Natural NKG2D Receptors In force · High confidence | In force | High confidence | |
| US 11,117,969 | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 11,453,713 | Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 12,145,976 | Modified A1-A2 domains of non-natural NKG2D ligands that bind non-natural NKG2D receptors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,957,714 | Non-Natural NKG2D Receptors That Do Not Directly Signal the Cells to Which They Are Attached In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 9 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 no status recorded